PressAugust 16, 2021 atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update
PressAugust 13, 2021 Core One Labs’ Clinics Submit Application to Treat Patient With Psilocybin Psychedelic-Assisted Therapy
PressAugust 12, 2021 Awakn Life Sciences Begins Trading on the OTCQB(R) Venture Market Under the Symbol ‘AWKNF’ on August 12th
PressAugust 9, 2021 Ketamine One to Provide Scent-Enabled Virtual Reality Via Exclusive Agreement for Psychedelic Molecules With OVR Technology
PressAugust 6, 2021 COMPASS Pathways plc to announce second quarter 2021 financial results on 11 August 2021
PressAugust 5, 2021 PharmaDrug Forms Research Collaboration with Terasaki Institute for Novel Ocular Drug Formulation Program to Deliver DMT and Other Tryptamines to Treat Eye Disease
PressAugust 4, 2021 Awakn Life Sciences Announces Its Second Location in the UK for “Awakn Clinics London,” Providing Treatment to the Largest City in the UK
PressAugust 3, 2021 MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology
PressJuly 29, 2021 Cybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5
PressJuly 27, 2021 Field Trip Health Ltd. to Commence Trading on the NASDAQ on July 29, 2021 Under the Symbol FTRP
PressJuly 26, 2021 Awakn Life Sciences Commences Trading on the OTC Market on July 26, 2021 Under the Symbol ‘AWKNF’
